With over 30 years of research, sales, business development and senior management experience in a range of blue-chip and smaller companies, Neil helped spin ReNewVax out of the University of Liverpool in 2022. With a biotech focus in oncology, immunology and infectious disease, Neil has an extensive network, having successfully raised capital in the public and private markets, negotiated acquisitions and licensing deals, and supported due diligence with a range of major companies and universities.